Biological Character of RetroNectin Activated Cytokine-Induced Killer CellsReport as inadecuate




Biological Character of RetroNectin Activated Cytokine-Induced Killer Cells - Download this document for free, or read online. Document in PDF available to download.

Journal of Immunology Research - Volume 2016 2016, Article ID 5706814, 11 pages -

Research Article

Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan 450008, China

Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan 450008, China

Received 29 March 2016; Accepted 26 May 2016

Academic Editor: Anil Shanker

Copyright © 2016 Lu Han et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Adoptive cell therapy ACT using autologous cytokine-induced killer CIK cells is a promising treatment for metastatic carcinomas. In this study, we investigated the impact of RetroNectin on the proliferation, phenotype alternation, cytokine secretion, and cytotoxic activity of CIK cells from pancreatic cancer patients. Furthermore, we treated 13 patients with metastatic or locally advanced pancreatic cancer using autologous RetroNectin-activated CIK cells R-CIK cells alone or in combination with chemotherapy. Compared with only CD3 activated CIK cells OKT-CIK cells, R-CIK cells showed stronger and faster proliferative ability, with a lower ratio of spontaneous apoptosis. Moreover, this ability continued after IL-2 was withdrawn from the culture system. R-CIK cells could also secrete higher levels of IL-2 and lower levels of IL-4 and IL-5 versus OKT-CIK cells. There was no difference between OKT-CIK and R-CIK cells in cytotoxic ability against lymphoma cell line K562. In patients who received auto-R-CIK cell infusion therapy, the overall objective response rate was 23.1%. Median survival time mOS after first R-CIK cell infusion was 10.57 months; the 1-year survival rate was 38.5%. No serious toxicity was associated with R-CIK cell infusion. In conclusion, RetroNectin may enhance antitumor activity of CIK cells: it is safe for use in treating pancreatic cancer.





Author: Lu Han, Yi-Man Shang, Yong-Ping Song, and Quan-Li Gao

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents